Alpha Tau Medical Ltd.

NASDAQ:DRTS

Biotechnology

Healthcare
$12.01 +0.42%

+$0.04 today

Market cap
$1.11B
Beta
1.20
P/E (TTM)
-15.2
EPS (TTM)
-$0.63
52W Low $2.85High $11.62

Volume 0.64M

Average 0.69M

DRTS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Alpha Tau Medical Ltd.NASDAQ: DRTS

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 68.2% from a year ago

Cash & equivalents stood at $8.44M at the end of Q1 FY2026, up 68.2% from a year earlier and down 47.2% from the prior quarter. Over 3 fiscal years it compounded at +39.9% a year.

Context

  • Cash & equivalents amounted to 7.8% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +68.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.44M-47.2% QoQ
Last fiscal yearDec 2025
$15.98M+16.4% YoY
Year agoMar 2025
$5.02M+68.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.2%——
1 year+16.4%——
3-year CAGR+39.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
15.98M USD
Year-over-year change
+16.4%
4-year CAGR
-8.9%

Cash & Equivalents vs competitors

How DRTS compares with its peers on the latest reported figures

  • DRTS's Mar 2026 cash & equivalents of $8.44M is the lowest of the 3 companies compared; the peer median is $212.8M.
  • Its year-over-year change of +68.2% is the highest of 2, against a peer median of +21.5%.
  • Cash & equivalents amounts to 7.8% of total assets for DRTS, versus a peer median of 38.8%.
DRTS Competitors Peer median
Cash & Equivalents for DRTS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AKTSAktis Oncology, Inc.Mar 2026$371.63M —-33.5%64.4%
CATXPerspective Therapeutics, Inc.Mar 2026$53.97M +21.5%+13.4%13.1%
DRTSAlpha Tau Medical Ltd.Mar 2026$8.44M +68.2%+39.9%7.8%
Peer median (excluding DRTS) $212.8M+21.5%-10.1%38.8%

Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents23.24M5.84M12.66M13.72M15.98M
Short-term Investments8.08M98.69M69.13M45.88M60.92M
Net Receivables480K32K19K332K36K
Inventory(8.17M)0(19K)00
Other Current Assets8.79M1.13M3.5M3.26M0
Total Current Assets32.64M106.48M85.76M64.23M78.3M
Property, Plant & Equipment (Net)7.55M13.28M21.16M21.54M26.88M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets0000928K
Other Non-current Assets2.03M391K471K432K479K
Total Non-current Assets9.57M13.67M21.63M21.98M28.28M
Total Assets42.22M120.15M107.39M86.2M106.58M
Account Payables1.2M1.42M2.57M3.53M3.87M
Short-term Debt001.06M1.01M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.41M1.34M(983K)389K3.78M
Total Current Liabilities4.41M4.34M7.1M8.68M10.51M
Long-term Debt53.96M05.61M5.56M6.35M
Deferred Tax Liabilities00001.02M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities18.62M5.63M3.6M3.34M5.35M
Total Non-current Liabilities72.59M10.15M15.81M14.86M18.97M
Total Liabilities76.99M14.49M22.91M23.54M29.48M
Common Stock00000
Retained Earnings(52.84M)(86.6M)(115.76M)(147.51M)(190.14M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(34.78M)105.66M84.48M62.67M77.1M
Total Debt53.96M5.19M13.28M12.54M13.73M
Net Debt30.73M(643K)619K(1.19M)(2.25M)

Alpha Tau Medical Ltd.

NASDAQ:DRTS

Intrinsic Alpha fair value

Locked

Current Price

$12.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.